Protagonist Therapeutics Profit Margin

Protagonist Therapeutics's profit margin stands at 35.85% as of June 2026. That compares with 25.55% in the prior-year period — up 40.3% year over year. That is above the Healthcare sector average of 15.29%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Protagonist Therapeutics reported 35.85% in profit margin versus 25.55% a year earlier — a 40.3% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Protagonist Therapeutics sits higher the Healthcare benchmark (15.29%) with a profit margin of 35.85%. That is roughly 134.4% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of 35.85% for Protagonist Therapeutics means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Protagonist Therapeutics's profit margin evolved across reporting periods, while the comparison chart places PTGX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.